SCHEMBL5134844

SCHEMBL5134844

CCCCN(Cc1cc(F)ccc1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
TSHR P16473 3/20 0.40
HDAC1 Q13547 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
CYP3A4 P08684 2/20 0.37
P2RX7 Q99572 1/20 0.37
CRHR1 P34998 2/20 0.36
NR1H3 Q13133 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
GNRHR P30968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137131 0.97 C5AR1 (0.41) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5137586 0.96 C5AR1 (0.40) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5135016 0.95 C5AR1 (0.41) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5135670 0.93 C5AR1 (0.43) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5135688 0.91 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137577 0.91 C5AR1 (0.43) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5136224 0.90 C5AR1 (0.41) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL5074315 0.90 C5AR1 (0.40) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL648787 0.90 C5AR1 (0.42) C5AR1TSHRHDAC1KDM4EALDH1A1
SCHEMBL649835 0.90 P2RX7 (0.43) C5AR1TSHRHDAC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed